Publication: An update on dry eye disease molecular treatment: Advances in drug pipelines
Loading...
Official URL
Full text at PDC
Publication Date
2014-07
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis
Citations
Exportar
Abstract
Introduction: Dry eye disease is a common disorder provoking changes in tear film and ocular surface. Untreated dry eye could cause ocular infections, corneal ulcer and blindness. Only a few drugs are authorized so far for the treatment of dry eye disease and the possibilities of evolution in this sector are immense. Consequently, a significant number of new potential solutions are under development or placed in the pharmaceutical pipeline, promising better results and lesser side effects.Areas covered: In this article, the corresponding literature and recent Phase III clinical trial data and the corresponding literature, for dry eye disease treatment are reviewed, revealing the new strategic movements in drug pipelines.Expert opinion: From the clinical trial results, the advancement in tear substitutes and secretagogues in addressing specific deficiencies of tear components even though not resolving the underlying conditions of the disease is evident. The vast majority of new compounds under development are anti-inflammatories, steroids, non-steroids and antibiotics; however, there are also some novel lubricating drops and mucin-tear secretagogues. A future aggressive therapy for dry eye, depending on the severity of the symptoms, would include combinations of soft steroids, anti-inflammatories, such as cyclosporine A, with the addition of the new polyvalent mucin and tear secretagogues.
Description
UCM subjects
Unesco subjects
Keywords
Citation
Fauchais AL, Martel C, Vidal E. [Epidemiology and physiopathogy of Sjogren’s syndrome]. Rev Prat 2012;622:218-20.
2. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;52:93-107 .. An important chapter of the 2007 Dry eye WorkShop report that summarizes prevalence and incidence data of the disease from various populations up to 2007.
3. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;52:75-92 .. Significant chapter of the 2007 Dry Eye WorkShop report that provides the definition and classification of the disease, as well as the factors that characterize and contribute to dry eye.
4. Linsen C, Missotten L. Physiology of the lacrimal system. Bull Soc Belge Ophtalmol 1990;238:35-44.
5. Dilly PN. Structure and function of the tear film. Adv Exp Med Biol 1994;350:239-47.
6. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004;238: 762-70.
7. Kastelan S, Lukenda A, Salopek-Rabatic J, et al. Dry eye symptoms and signs in long-term contact lens wearers. Coll Antropol 2013;37(Suppl 1):199-203.
8. Lemp MA. Epidemiology and classification of dry eye. Adv Exp Med Biol 1998;438:791-803.
9. Bron AJ. Diagnosis of dry eye. Surv Ophthalmol 2001;45(Suppl 2):S221-6.
10. Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea 2012;315:472-8.
11. Viso E, Rodriguez-Ares MT, Abelenda D, et al. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci 2012;536:2601-6.
12. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;52:108-52 .. An important chapter of the 2007 Dry Eye WorkShop report that provides the different tests used for the diagnostic of the dry eye disease and commentary about their utility in clinical setting.
13. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinica measurements of dry eye. Cornea 2004;233:272-85. Significant study showing the complexity of the dry eye disease diagnostic and classification that explain the variability of results obtained in patients with this disease.
14. Johnson ME. The association between symptoms of discomfort and signs in dry eye. Ocul Surf 2009;7:199-211.
15. Pult H, Purslow C, Murphy PJ. The relationship between clinical signs and dry eye symptoms. Eye (Lond) 2011;254:502-10.
16. Narayanan S, Miller WL, Prager TC, et al. The diagnosis and characteristics of moderate dry eye in non-contact lens wearers. Eye Contact Lens 2005;313:96-104.
17. Turner AW, Layton CJ, Bron AJ. Survey of eye practitioners’ attitudes towards diagnostic tests and therapies for dry eye disease. Clin Experiment Ophthalmol 2005;334:351-5.
18. Nichols KK, Nichols JJ, Zadnik K. Frequency of dry eye diagnostic test procedures used in various modes of ophthalmic practice. Cornea
2000;194:477-82.
19. Barabino S, Chen Y, Chauhan S, et al. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res 2012;313:271-85.
20. Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol 2013;321:19-41.
21. Pult H, Purslow C, Berry M, et al. Clinical tests for successful contact lens wear: relationship and predictive potential. Optom Vis Sci 2008;8510:E924-9.
22. Sambursky R, Davitt WF III, Latkany R, et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol 2013;1311:24-8.
23. Blackie CA, Solomon JD, Scaffidi RC, et al. The relationship between dry eye symptoms and lipid layer thickness. Cornea 2009;287:789-94.
24. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011;1515:792-8; e1. Significant paper that evaluates the use of the tear osmolarity test for the diagnosis of dry eye disease.
25. McGinnigle S, Naroo SA, Eperjesi F. Evaluation of dry eye. Surv Ophthalmol 2012;574:293-316.
26. Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci 2010;5112:6125-30.
27. Sacks LV, Shamsuddin HH, Yasinskaya YI, et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000 -- 2012. JAMA 2014;3114:378-84.
28. Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res 2001;221:8-18.
29. The Gallup Organization I. The 2008 gallup study of dry eye sufferers. Multi-Sponsor Surveys, Inc, Princeton, NJ; 2008.
30. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;52:163-78 .. Significant chapter of the 2007 Dry Eye WorkShop report that summarizes the options for therapy and defines a strategy for management of the dry eye disease.
31. Luo L, Li DQ, Corrales RM, et al. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens 2005;315:186-93.
32. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004;4512:4293-301.
33. Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B 2006;78:675-8.
34. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;1074:631-9.
35. Calias P, Cook C, Jaffe M, et al. Enhanced delivery of a therapeutic to ocular tissues through iontophoresis. WO2009108626; 2009.
36. Patane MA, Cohen A, From S, et al. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol 2011;5:633-43.
37. Assil KK, Massry G, Lehmann R, et al. Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. J Cataract Refract Surg 1997;235:750-7.
38. Bron A, Denis P, Hoang-Xuan TC, et al. The effects of Rimexolone 1% in postoperative inflammation after cataract extraction. A double-masked placebocontrolled study. Eur J Ophthalmol 1998;81:16-21.
39. Kavuncu S, Horoz H, Ardagil A, et al. Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery. Int Ophthalmol 2008;284:281-5.
40. Vico-Ruiz E, Benitez-Del-CastilloSanchez JM, Cuina-Sardina R, et al. 0.1% dexamathasone and 1% rimexolone. A comparative study in the postoperative treatment after cataract extraction. Arch Soc Esp Oftalmol 2009;846:299-304.
41. Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative antiinflammatory use. Int Ophthalmol 2012;325:507-17.
42. McNamara T, Chandler SP, Kida T. Ophthalmic NSAIDS as adjuvants. US20110054031; 2011.
43. Walters TR, Goldberg DF, Peace JH, et al. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials. Ophthalmology 2014;1211:25-33.
44. Wang QW, Yao K, Xu W, et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica 2013;2294:187-94.
45. Prasher P. Acute corneal melt associated with topical bromfenac use. Eye Contact Lens 2012;384:260-2.
46. Hou J, Townson SA, Kovalchin JT, et al. Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci USA 2013;11010:3913-18
47. Barnes TM, Hou J, King BM. Chimeric IL-1 receptor type I agonists and antagonists. WO2012016203; 2012.48. Furfine ES, Hou J, Collins K, et al. EBI-005: an Interleukin-1 receptor inhibitor designed for the treatment of dry eye syndrome. Association for research in vision and ophthalmology (ARVO) 2012; E-Abstract: 2340/A357.
49. Okanobo A, Chauhan SK, Dastjerdi MH, et al. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol 2012;1541:63-71.
50. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;92:R28.
51. Venkiteshwaran A. Tocilizumab. MAbs 2009;15:432-8.
52. Sato T, Minakuchi S, Mochizuki M, et al. Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis. Clin Ophthalmol 2014;8:187-90.
53. Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 2011;195:382-3.
54. Tappeiner C, Heinz C, Ganser G, et al. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 2012;396:1294-5.
55. Fishman P. Pharmaceutical composition comprising a3 adenosine receptor agonist (IB-MECA/CF-101) for treatment of psoriasis. WO2011027348; 2011.
56. Bar-Yehuda S, Luger D, Ochaion A, et al. Inhibition of experimental autoimmune uveitis by the A3 adenosine receptor agonist CF101. Int J Mol Med 2011;285:727-31.
57. Ashar JN, Mathur A, Sangwan V. CF101 for dry eye. Ophthalmology 2011;1185:1011-12; author reply 2 58. Bague S, Lambert G, Philips B, et al. Ophthalmic emulsions containing an immunosuppressive agent. US20128298569; 2012.
59. Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv 2012;2012:604204.
60. Daull P, Lallemand F, Philips B, et al. Distribution of cyclosporine a in ocular tissues after topical administration of cyclosporine a cationic emulsions to pigmented rabbits. Cornea 2013;323:345-54.
61. Lemp AM, Baudouin C, Amrane M, et al. Poor correlation between dry eye disease (DED) signs and symptoms in a Phase III randomized clinical trial. Association for research in vision and ophthalmology (ARVO) 2011; E-Abstract: 3821/D954.
62. Yavuz B, Bozdag Pehlivan S, Unlu N. An overview on dry eye treatment: approaches for cyclosporin a delivery. ScientificWorldJournal 2012;2012:194848.
63. Burnier J, Gadek T, Naud F. Crystalline pharmaceutical and methods of preparation and use thereof. US20118080562; 2011.
64. Sun Y, Zhang R, Gadek TR, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther 2013;29(4):395-402.
65. Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, doublemasked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol 2012;1536:1050-60; e1.
66. Yandrapu S, Kompella UB. Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. J Ocul Pharmacol Ther 2013;29(2):236-48.
67. Brazzell RK, Haque RM, Brubaker KE, et al. Method of treating dry eye disease with azithromycin. US20100190734; 2010.
68. Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea 2013;321:44-53.
69. Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol 2013;7:1797-803.
70. Utine CA. Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections. Clin Ophthalmol 2011;5:801-9.
71. Veldman P, Colby K. Current evidence for topical azithromycin 1% ophthalmic solution in the treatment of blepharitis and blepharitis-associated ocular dryness. Int Ophthalmol Clin 2011;514:43-52.
72. Nichols JJ, Bickle KM, Zink RC, et al. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye. Eye Contact Lens 2012;382:73-9.
73. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;171:1-14.
74. Rihl M, Ulbricht K, Schmidt RE, et al. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren’s syndrome. Rheumatology (Oxford) 2009;487:796-9.
75. Yavuz S, Asfuroglu E, Bicakcigil M, et al. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren’s syndrome. Rheumatol Int 2011;318:1045-9.
76. Opremcak EM. Plaquenil toxicity. Insight 2013;383:15.
77. Vanderzee G, Tassi D. New trends in early diagnosis of hydroxychloroquine toxic retinopathy. Optometry 2012;835:200-7.
78. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody. Semin Oncol 1999;265(Suppl 14):66-73.
79. Rogers JL, Serafin DS, Timoshchenko RG, et al. Cellular targeting in autoimmunity. Curr Allergy Asthma Rep 2012;126:495-510.
80. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome. Ann Rheum Dis 2013;726:1026-31.
81. Cumberlidge G, Lama T, Meerovitch K. Beta-turn peptidomimetic cyclic compounds for treating dry eye. US20128293713; 2012.
82. Wang ZX, Sun XG. The effect of nerve growth factor on proliferation and expression of mucin gene in human conjunctival goblet cells. Zhonghua Yan Ke Za Zhi 2007;4310:928-31.
83. Jain P, Li R, Lama T, et al. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Exp Eye Res 2011;934:503-12.
84. Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol 2013;7:1275-85,
85. Tarnawski AS, Chai J, Pai R, et al. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci 2004;492:202-9.
86. Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci 2009;547:1500-7.
87. Urashima H, Okamoto T, Takeji Y, et al. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea 2004;236:613-19.
88. Sumida SI, Ishikawa S. A pharmaceutical composition comprising rebamipide. WO2009154304, US 20110124682; 2009.
89. Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology 2012;11912:2471-8.
90. Ogawa T, Watanabe N, Okumura Y. Method for preventing or treating dry eye or disease caused therefrom. US19985830913; 1998.
91. Munakata W, Liu Q, Shimoyama T, et al. Ecabet sodium attenuates reactive oxygen species produced by neutrophils after priming with bacterial lipopolysaccharides. Luminescence 2003;186:330-3.
92. Shimoyama T, Fukuda Y, Fukuda S, et al. Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. J Gastroenterol 1996;31(Suppl 9):59-62.
93. Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res 1998;673:341-6.
94. Murakami T, Fujihara T, Horibe Y, et al. Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res 2004;362:89-93.
95. Fujihara T, Murakami T, Nagano T, et al. INS365 suppresses loss of corneal epithelial integrity by secretion of mucinlike glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther 2002;184:363-70.
96. Takamura E, Tsubota K, Watanabe H, et al. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol 2012;9610:1310-15.
97. Kamiya K, Nakanishi M, Ishii R, et al. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond) 2012;2610:1363-8.
98. Koh S, Ikeda C, Takai Y, et al. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol 2013;575:440-6 .
99. Business Wire. Santen and inspire announce approval of DIQUASTM for Dry Eye Treatment in Japan. Available from: http://www.businesswire.com/news/home/20100416005914/en/SantenInspire-Announce-ApprovalDIQUASTM-Dry-Eye [Last accessed 3 January 2014].
100. Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf 2013;114:246-58.
101. Simmons PA, Vehige J. Ophthalmic compositions useful for improving visual acuity. US20100184664; 2010.
102. Garrett Q, Simmons PA, Xu S, et al. Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci 2007;484:1559-67.
103. Baudouin C, Cochener B, Pisella PJ, et al. Randomized, phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease. Eur J Ophthalmol 2012;225:751-61.
104. McGinnigle S, Eperjesi F, Naroo SA. A preliminary investigation into the effects of ocular lubricants on higher order aberrations in normal and dry eye subjects. Cont Lens Anterior Eye 2014;37(2):106-10.
105. McCann LC, Tomlinson A, Pearce EI, et al. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea 2012;311:1-5.
106. Rah MJ. A review of hyaluronan and its ophthalmic applications. Optometry 2011;821:38-43.
107. Lee JH, Ahn HS, Kim EK, et al. Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea 2011;302:175-9.
108. Vogel R, Crockett RS, Oden N, et al. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). Am J Ophthalmol 2010;1494:594-601.
109. Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronatecontaining artificial tears reduces ocular
surface damage in patients with dry eye. Br J Ophthalmol 2002;862:181-4.
110. Baeyens V, Bron A, Baudouin C. Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease. J Fr Ophtalmol 2012;356:412-19.
111. Dumbleton K, Woods C, Fonn D. An investigation of the efficacy of a novel ocular lubricant. Eye Contact Lens 2009;353:149-55.
112. Baeurle SA, Kiselev MG, Makarova ES, et al. Effect of the counterion behavior on the frictional--compressive properties of chondroitin sulfate solutions. Polymer (Guildf) 2009;507:1805-13.
113. Konat Zorzi G, Contreras-Ruiz L, Parraga JE, et al. Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles. Mol Pharm 2011;85:1783-8.
114. Llamas-Moreno JF, Baiza-Duran LM, Saucedo-Rodriguez LR, et al. Efficacy and safety of chondroitin sulfate/xanthan gum versus polyethylene glycol/propylene glycol/hydroxypropyl guar in patients with dry eye. Clin Ophthalmol 2013;7:995-9.
115. Oechsner M, Keipert S. Polyacrylic acid/polyvinylpyrrolidone bipolymeric systems. I. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye-syndrome. Eur J Pharm Biopharm 1999;472:113-18.
116. Villani E, Laganovska G, Viola F, et al. A multicenter, double-blind, parallel group, placebo-controlled clinical study to examine the safety and efficacy of T-Clair SPHP700-3 in the management of mild to moderate dry eye in adults. Cornea 2011;303:265-8.
117. Fel A, Aslangul E, Le Jeunne C. Eye and corticosteroid’s use. Presse Med 2012;414:414-21.
118. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004;1383:444-57.